Wearing a bleeper device during catheterizations helped lower radiation exposure to operators by about one third in the RadiCure Study. Results from the late-breaking randomized controlled clinical trial were presented May 30 at the Society for Cardiovascular Angiography and Interventions (SCAI) scientific session in Las Vegas.

Significant per-patient savings and better outcomes may be possible with an atherectomy device presented as a late-breaking clinical trial May 30 at the Society for Cardiovascular Angiography and Interventions (SCAI) scientific session in Las Vegas. Compared with Medicare patients, ORBIT II patients saw a cost reduction of over $2,500 per patient and a shorter hospital stay by up to three days.

A hospital in Kentucky agreed to pay almost $41 million to put a case alleging unnecessary cardiac stenting and diagnostic catheterizations behind it.

One third of patients who were discharged after a PCI failed to fill their clopidogrel prescriptions within three days, according to a study published online May 28 in Journal of the American Heart Association, at the risk of serious consequences. Findings showed that the time following hospital release to the filling of the prescription dramatically influences outcomes.

Spectranetics Corp. and AngioScore penned a $230 million deal to serve the peripheral and coronary markets by making AngioScore a wholly owned subsidiary of Spectranetics.  

The Accreditation for Cardiovascular Excellence (ACE) is proud to announce the participation of every ACE Board Member at the 2014 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions in Las Vegas, NV, May 28-31, 2014. First, Charles E. Chambers, MD, FSCAI, President-Elect of SCAI and ACE Board Member, will kick-off SCAI's inaugural Cath Lab Leadership Boot Camp, a unique two-day educational event designed to address the needs of cath lab managers and directors and those who aspire to those roles.

Covidien today announced nine-month data from the VISIBILITY Iliac study, which confirms the safety and effectiveness of the treatment of lesions of the common and external iliac arteries with the Visi-Pro(tm) balloon-expandable stent system. Results were presented by co-National Principal Investigator John Rundback, MD, Holy Name Medical Center, Teaneck, N.J., during an oral presentation this week at EuroPCR Scientific Congress in Paris.

Continuing its commitment to bringing advanced and clinically relevant interventional technologies to market, Medtronic, Inc. today announced CE (Conformité Européene) mark and launch of the NC Euphora(TM) Noncompliant Balloon Dilatation Catheter. The NC Euphora Balloon Catheter is now available in Europe and other countries outside of the United States that recognize the CE mark. It is not yet available in the United States.